Opportunity Summary
Issuer/operator: HealthInno, Albuquerque, New Mexico
Opportunity: Health ImpACT Challenge: Health Tech Companies & Startups
Opportunity type: State-backed healthcare innovation pilot and real-world validation pathway
Deadline: No fixed closing deadline is published. HealthInno is currently accepting company information and reviewing submissions as healthcare priorities and Challenge Themes are developed.
Applicant-relevant value: Access to structured, time-bound evaluations in New Mexico healthcare settings, often one to three months. HealthInno advertises $844,000 in coordinated statewide healthcare innovation support for the broader initiative, but it does not promise a cash award, procurement, guaranteed sale, or fixed vendor funding amount to an applying company.
Match/cost share: None stated. This is a pilot and validation opportunity rather than a conventional grant award.
Eligibility and Readiness
HealthInno says any U.S.-based health technology company may apply. A strong-fit company should have a pilot-ready product that can be deployed now, can demonstrate value in a structured evaluation, and can operate in real clinical workflows. FDA-regulated products must already be cleared; solutions that do not require FDA clearance may also qualify. Companies actively seeking clearance, relying on clinical trials before deployment, or still at the pre-product stage are not a fit.
HealthInno reviews submissions for readiness, feasibility, and alignment. Selected companies may be shared with New Mexico healthcare decision makers for discussion, and aligned partners may move into a scoped evaluation. Submission does not guarantee selection, a pilot, procurement, or a customer.
Submission Requirements
Companies submit information through HealthInno’s online application and upload a current pitch deck, with PDF preferred. Atlas does not infer additional applicant-controlled fields or materials that are not publicly enumerated.
Nonagon N9+ Fit
N9+ Fit Score: 94/100. Health ImpACT specifically seeks technology that can extend care across distance, support virtual-first workflows, home-based care, continuity, and remote support. FDA 510(k) K223785 identifies the N9+ as a Class II device and states that the N9+ can measure, record, and transmit examination data and support physician counseling and transmission over an IP network. That creates a strong, direct pilot-fit pathway without forcing the use case.
Atlas Opportunity Score: 91/100. The opportunity is current, state-backed, directly open to U.S. health technology companies, and designed for real-world pilot validation. The principal limitations are the absence of a guaranteed pilot, procurement, fixed vendor award, or published closing date.
Dr. Miltie/QC Healthcare status: TRUE direct-vendor opportunity. Atlas has not submitted an application. Marc Poulshock review and authorization are required before any company submission. Any submission must use verified company facts and an approved current pitch deck and must not invent organizational, regulatory, reference, or performance claims.
Controlling sources: HealthInno Health ImpACT company application; Health ImpACT Challenge overview; FDA 510(k) K223785.
Verified September 12, 2026. Atlas preserves the distinction between the broader $844,000 state-backed initiative and any applicant-specific value: HealthInno does not publish a guaranteed vendor award.